Patient with Refractory Multiple Myeloma Developing Eosinophilia after Lenalidomide Treatment and Lung Cancer 9 Months Later: Case Report and Review of the Literature

Sekiguchi, Y.; Shimada, Asami; Imai, Hidenori; Wakabayashi, Mutsumi; Sugimoto, Keiji; Nakamura, Noriko; Sawada, Tomohiro; Komatsu, Norio; Noguchi, Masaaki

doi:10.1007/s12288-014-0355-7

Cited by 10 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also all the 3 patients were under antineoplastic treatment. 6,7,8 This case report is the first report from India (best known to our knowledge) in which a direct correlation between thalidomide use and development of eosinophilia can be observed. During hospitalization, most frequent causes of eosinophilia like allergic reaction, tropical parasitic disease and adrenal insufficiency were ruled out by IgE, microfilaria, serum cortisol investigations in our patient.…”

Section: Discussionmentioning

confidence: 66%

Lepra tip 2 reaksiyonlarında talidomid tedavisinde ilaç yan etkisi olarak ikincil eosinofili: zorunlu bir sorumluluk

Thangaraju

Venkatesan

Chandu

et al. 2019

Cukurova Medical Journal

View full text Add to dashboard Cite

Limited data are available on eosinophilia as a drug adverse event with immunosuppressant and modulator. We report a case of 40 year old male patient treated with thalidomide for lepra reaction developed thalidomide induced eosinophilia. Eosinophil count rose during thalidomide treatment and decreased in the periods when the patient was off the treatment. Eosinophilia as an adverse event due to thalidomide has been described rarely except in a case of congener Lenalidomide. This case shows a clear temporal relationship between thalidomide and eosinophilia. With reference to this case, monitoring of patients receiving similar treatment can be increased to detect and prevent any possible adverse drug reactions before it adds up to the suffering of the patient in turn improving the quality of medical services and patient care as well. Thus the quality has been improved and managed in the current case.

show abstract

Section: Discussionmentioning

confidence: 66%

Lepra tip 2 reaksiyonlarında talidomid tedavisinde ilaç yan etkisi olarak ikincil eosinofili: zorunlu bir sorumluluk

Thangaraju

Venkatesan

Chandu

et al. 2019

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…Eosinophilia secondary to lenalidomide is an adverse event not described in the summary of product characteristics, and there are very few reported cases in scientific literature. We have only found two reported cases of eosinophilia as a result of lenalidomide use for the treatment of multiple myeloma . Foti et al published the case of a 78‐year‐old woman who suffered from DRESS syndrome.…”

Section: Case Descriptionmentioning

confidence: 96%

“…Lenalidomide provides co‐stimulation of both human T cells as well as Natural Killer T (NKT) cells; consequently, the production of several cytokines is activated. NKT cells and these cytokines, such as IL‐6, could have effects on diverse innate cells including eosinophils …”

Section: Case Descriptionmentioning

confidence: 99%

“…Eosinophilia secondary to lenalidomide is an adverse event not described in the summary of product characteristics, 3 alteration without other complications, as it is the case in the letter reported by Sekiguchi, which was very similar to our case, with the onset of the eosinophilia immediately after starting the lenalidomide therapy, and without associated complications. 7 Moreover, cases of eosinophilia secondary to thalidomide therapy have been reported. 9,10 This could be explained because the chemical structure and mechanism of action of both drugs are quite similar.…”

Section: Case Descriptionmentioning

confidence: 99%

See 1 more Smart Citation

Eosinophilia secondary to lenalidomide therapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Risk assessment of lung resection for lung cancer according to pulmonary function has been systematically reviewed ( 7 ). Despite the increasing number of therapeutic improvements for NSCLC proposed, the poor survival rate of patients with NSCLC was reported to be <15% over 5 years, which has caused a number of problems in clinical practice ( 8 , 9 ). Therefore, more efficient anti-NSCLC agents are required to explore alternative treatments for patients with NSCLC in preclinical and clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Calotropin regulates the apoptosis of non‑small cell cancer by regulating the cytotoxic T‑lymphocyte associated antigen 4‑mediated TGF‑β/ERK signaling pathway

2018

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies that is responsible for a high level of cancer-associated mortalities worldwide. Previous evidence has shown that Calotropin is an upstream activator of protein kinase B, which can further inhibit the growth and promote the apoptosis of NSCLC cells. In the present study, the efficacy of Calotropin on growth, aggressiveness and apoptosis of NSCLC cells was investigated, as well as the potential underlying mechanism. The results demonstrated that Calotropin inhibited H358 cell growth, migration and invasion. Flow cytometry assay showed that Calotropin promoted the apoptosis of H358 cells in vitro. Western blot analysis demonstrated that Calotropin inhibited fibronectin (FN), Vimentin (VIM) and E-cadherin (Eca) protein expression levels in H358 cells in vitro. In addition, Calotropin treatment upregulated pro-apoptosis gene expression, including caspase-3, caspase-8 and apoptotic protease activating factor-1, and downregulated anti-apoptosis gene expression, including P53, B-cell lymphoma (Bcl) 2 and Bcl-2-like protein 2 in H358 cells. The results also revealed that the expression levels of cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) were decreased by Calotropin treatment in H358 cells. Analyses of the underlying mechanism indicated that Calotropin inhibited transforming growth factor-β (TGF-β) and extracellular signal-regulated kinase (ERK) expression. Overexpression of CTLA-4 inhibited Calotropin-mediated downregulation of TGF-β and ERK expression in H358 cells. In vivo assay revealed that Calotropin administration significantly inhibited tumor growth and prolonged animal survival over the 120-day observation period. Immunohistochemistry demonstrated that the number of apoptotic cells increased and the expression levels of CTLA-4 were decreased in the Calotropin-treated tumor group when compared with control. In addition, the expression levels of TGF-β and ERK were downregulated in the Calotropin-treated tumor group compared with control. In conclusion, the results of the present study indicated that Calotropin administration regulated NSCLC apoptosis by downregulating the CTLA-4-mediated TGF-β/ERK signaling pathway, suggesting that Calotropin may be a potential anti-cancer agent for the treatment of NSCLC.

show abstract

Patient with Refractory Multiple Myeloma Developing Eosinophilia after Lenalidomide Treatment and Lung Cancer 9 Months Later: Case Report and Review of the Literature

Abstract: A 78-year-old man was diagnosed as having advanced symptomatic IgG multiple myeloma in June 2008.

Cited by 10 publications

References 16 publications

Lepra tip 2 reaksiyonlarında talidomid tedavisinde ilaç yan etkisi olarak ikincil eosinofili: zorunlu bir sorumluluk

Lepra tip 2 reaksiyonlarında talidomid tedavisinde ilaç yan etkisi olarak ikincil eosinofili: zorunlu bir sorumluluk

Eosinophilia secondary to lenalidomide therapy

Calotropin regulates the apoptosis of non‑small cell cancer by regulating the cytotoxic T‑lymphocyte associated antigen 4‑mediated TGF‑β/ERK signaling pathway

Contact Info

Product

Resources

About